Objective: Endovascular popliteal artery aneurysm repair (EPAR) is increasingly used over open surgical repair (OPAR). The purpose of this study was to analyze the available literature on their comparative outcomes.
Popliteal artery aneurysm (PAA) repair is performed prophylactically in asymptomatic aneurysms >2 cm or in symptomatic PAAs of any size to prevent ischemic complications from distal embolization or thrombosis that may lead to limb loss. During the last five decades, open repair of PAAs (OPAR) has proved to be extremely durable with excellent long-term patency (primary patency up to 76% at 5 years) 1, 2 and is thus considered the "gold standard" for repair. As in all aspects of vascular surgery, endovascular repair of PAAs (EPAR) has gained in popularity because of the decreased early morbidity with endovascular procedures. Since its reported use in 1994 by Marin et al, 3 EPAR has gained in popularity as a minimally invasive method to exclude PAAs with a stent graft. Early reports revealed high thrombotic complications, 4 but advances in technology and selection of patients have improved results. [5] [6] [7] The literature is limited to one randomized controlled trial 8 and numerous retrospective studies looking at outcomes of OPAR vs EPAR. 5, 7, [9] [10] [11] [12] [13] [14] [15] The objective of this study was to evaluate all available comparative studies of OPAR vs EPAR by meta-analysis. Our hypothesis is that OPAR has superior patency outcomes with higher complications compared with EPAR. The results of this meta-analysis and our clinical experience will be used to propose a treatment algorithm for the management of PAA.
METHODS
Review protocol. The criteria for study selection, methods of analysis, and investigated outcomes were selected before analysis. The protocol was not registered at the International Prospective Register of Systematic Reviews. Meta-analysis of Observational Studies in Epidemiology guidelines were used to report methods and findings (Supplementary Table I , online only). 16 No funding was provided for this research.
Study eligibility criteria. Selection of studies was aimed at collecting all studies that included both treatment strategies of PAA, endovascular repair and open repair. The following eligibility criteria were specified: (1) the design was a randomized controlled trial, retrospective or prospective cohort study with a minimum of five patients in each group; (2) the population included adult patients undergoing repair of PAA; interventions for nonaneurysmal indications (occlusive disease, trauma) were excluded; (3) the study included both interventions, OPAR (no limitations to surgical technique) and EPAR (with stent graft, no limitation to other technical details); studies with only one treatment type were excluded; and (4) the study reported adequate outcomes for analysis. All studies meeting these criteria were included, regardless of the symptomatic status of the patient at presentation.
Outcome measures. Primary and secondary patency rates at 1 year and 3 years were the primary outcomes of interest. Secondary outcomes included complications, length of stay, reinterventions, amputations, and 30-day mortality. Complications were self-reported in each study. Total complications included all complications defined by individual studies. There was variation in the definition of complications among studies (eg, wound complications), and when they were subdivided, they were collected and reported separately.
Search methods. The authors searched electronic databases including MEDLINE and Embase during January 2016. Search dates were limited from January 1994 to January 2016 as publications before 1994 would not have included EPAR. The search terms used medical subject headings including "popliteal," "artery," and "aneurysm." The only limitation used was a restriction to journals published in English. No contact with authors of manuscripts was necessary. Two reviewers (A.E.L., M.A.S.) independently screened the titles and abstracts of all records. Before data collection, an electronic spreadsheet was created to collect variables of interest. Two reviewers extracted the study variables independently. All discrepancies were resolved by consensus led by the senior author (E.D.A.). Reviewers were trained health researchers and physicians, with immediate access to senior authors as needed.
Assessment of risk for bias. The risk of bias was assessed using a modified version of the NewcastleOttawa Scale, which accommodates observational and randomized trials. 17, 18 Two reviewers (A.E.L., M.A.S.)
independently assessed the risk of bias using the scale consisting of three categories (selection, comparability, and outcome), with each category consisting of questions corresponding to the quality of the study. A study received a star in each category when it met the definition for high quality. Studies were deemed low quality (0-6 stars), medium quality (7-8 stars) , and high quality (9 stars). Newcastle-Ottawa Scale scores are shown in Table I and broken down by category in Supplementary  Table II (online only) .
Statistical analysis. The meta-analyses were performed through the user-programmed metan procedure in Stata 14 (StataCorp LP, College Station, Tex). With the exception of length of stay and PAA size, the outcome variables were dichotomous, and in most cases effects were presented as odds ratio (OR). As outlined in Borenstein et al, 19 we employed random-effects models, estimating between-study variance through the DerSimonian-Laird method. There is no universally accepted way to report patency variables from KaplanMeier curves for interpretation in meta-analysis. Patency rates were analyzed as risk ratios (RRs), where "risk" was the Kaplan-Meier estimate subtracted from 1. The sample totals of subjects were captured from the total number of patients included in a given study, as has previously been performed. 20 A corresponding 95%
confidence interval (CI) is presented for each variable. For each outcome, we provide z-tests for the estimated overall effect; the c 2 test for between-study variability;
and the I 2 statistic, which gives the estimated percentage of between-study variation in the effect size that is true variation (as opposed to random). P values < .05 were considered statistically significant.
RESULTS
Results of search. A total of 614 articles were identified and reviewed for inclusion. Full-text articles were carefully reviewed, and a total of 14 studies met the approved selection criteria (Fig 1) . [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [26] [27] [28] [29] Included studies. Studies included in the analysis are shown in Table I . The studies ranged from 2005 to 2016, with almost half of the studies published in the last year of analysis. The studies consist of retrospective single-center studies, 5, 7, [9] [10] [11] [12] [13] [14] [15] retrospective multicenter studies, 28 retrospective administrative data sets, 29 self-reported registries, 26, 27 and randomized controlled trials. 6 The pooled total number of PAA repairs was 4880, with 3915 (80%) undergoing OPAR and 1210 (20%) undergoing EPAR. There was considerable variation in the outcomes reported in each study, as shown in Table I . PAA presentation varied with each study; three studies reported on asymptomatic patients only, 6,26,29 one study did not report symptomatic status, 15 and the remaining studies had various proportions of symptomatic patients ranging from 18% to 53%. Symptomatic status was ill-defined; the studies typically included patients with acute ischemia and symptoms (claudication, compression, and rupture). The overall quality of studies was low, with the exception of a single prospective randomized controlled trial. Demographics. Demographic information is shown in Table II . OPAR patients were more likely to be younger (standard mean difference [SMD], À0.798; P < .001) with no other differences in comorbidities compared with EPAR. There was significant heterogeneity in several of the demographic variables reported across the studies; however, the weighted means were overall similar. OPAR was more likely to have worse runoff (OR, 1.949; P ¼ .01), with 37% having less than two-vessel runoff compared with 22.8% of EPAR patients. There was no difference in aneurysm size, with a mean size of approximately 30 mm in both groups.
Outcomes. Primary and secondary outcomes are shown in Table III Patency outcomes. Patency outcomes were reported in the majority of studies (11/14) , with midterm outcomes to 3 years reported in a few (5/14). For OPAR, the weighted mean for primary patency at 1 year and 3 years was 88.3% (11 studies; 95% CI, 83.4-92.2) and 79.4% (6 studies; 95% CI, 74.5-83.8), whereas the secondary patency at 1 year and 3 years was 92.3% (9 studies; 95% CI, 88.7-95.2) and 86.6% (5 studies; 95% CI, 82.7-90.0), respectively. For EPAR, the weighted mean for primary patency at 1 year and 3 years was 81.2% (11 studies; 95% CI, 72.7-88.4) and 68.2% (6 studies; 95% CI, 63.6-72.7), whereas the secondary patency was 86.3% (9 studies; 95% CI, 73.4-95.4) and 80.0% (5 studies; 95% CI, 74.3-85.2), respectively.
At 1 year (RR, 0.607; 95% CI, 0.416-0.886; P ¼ .01), 2 years (RR, 0.661; 95% CI, 0.477-0.917; P ¼ .013), and 3 years (RR, 0.580; 95% CI, 0.395-0.852; P ¼ .006.), OPAR was less likely to lose primary patency than EPAR (Table III) . Forest plots of 1 year and 3 years are shown in Figs 3 and 4. Studies consistently favored OPAR at 1 year and 3 years; however, there was significant heterogeneity within the primary patency variable. Sensitivity analysis eliminating single studies and studies with only symptomatic patients was performed. The sensitivity analysis was unable to determine which study led to the significant heterogeneity within the analysis. Secondary patency also seemed to favor OPAR; however, it did not Patency reported: 1, 1-year primary patency; 2, 2-year primary patency; 3, 3-year primary patency; 4, 1-year secondary patency; 5, 2-year secondary patency; 6, 3-year secondary patency. reach statistical significance. This is demonstrated on the forest plots at 3 years, whereas at 1 year, there was much more variation.
DISCUSSION
The advantages of EPAR are clear; it is less invasive and potentially less morbid. The application of endovascular repair has gained in popularity, as evidenced by the number of articles published in the past years. However, the available literature guiding treatment for PAA is limited to mostly small, single-center experiences or larger database/registry-based studies in which many of the pertinent clinical data are absent. This study compiled the available literature on PAA repair from comparative studies. To date, no previous study has been able to show any major differences between the two treatment modalities. This may be due to low statistical power, given the small sizes of most studies. This study demonstrated the beneficial short-term outcomes of EPAR with lower wound complications and short hospital length of stay. However, primary but not secondary patency favors OPAR out to 3 years.
Study selection included only studies with both treatment options to minimize bias toward one modality. The literature review yielded 14 articles with a range of study locations and designs. Most of the studies included in this analysis were single-center retrospective studies and published in the past 2 years. [12] [13] [14] [15] 26, 27 Meta-analyses on this subject have been previously performed and showed comparable results between the two modalities. 30, 31 These studies were unable to detect any major differences. The first meta-analysis was published in 2008 and included the results of three studies with 141 patients included in the analysis. 30 A more recent meta-analysis was published in 2015, reporting five studies with 652 patients, but the authors excluded two major studies 5, 9 that were misidentified as duplicate data. 31 However, since its publication, the number of comparative studies has more than doubled. [12] [13] [14] [15] 26, 27, 29 The present study encompasses >4500 patients undergoing PAA repair, across a variety of nationalities, databases, and institutions, giving a real-world experience of PAA outcomes during the past decade. Our study suggests that overall, the patient comorbidities were similar among the two treatment groups in all these comparative analyses. The notable differences were that OPAR patients were slightly younger and had worse tibial runoff at the time of presentation. Poor tibial runoff has been associated with worse outcomes for both EPAR 32 and OPAR. 2 In this series, OPAR was almost twofold more likely to have worse runoff (less than twovessel runoff) compared with EPAR (hazard ratio [HR], 1.949). This may suggest some selection biases; patients with worse runoff are undergoing OPAR.
OPAR had worse wound complications and higher length of stay. Wound complications were fivefold more likely with OPAR (OR, 5.182), and the incidence ranged from 7.3% to 22% across all studies. Length of stay was also significantly longer (SMD, 2.158) compared with EPAR. This is not surprising as a majority of EPAR procedures can be performed completely percutaneously, almost negating the risk of wound complications and prolonged admissions. However, some of the complications of the percutaneous approach might not have been accurately collected, particularly in administrative studies. In addition, despite the fivefold increase in wound infections, there was no difference in Huang (2014) Leake (2016) Ronchey (2015) Wooster (2016) Stone (2013) Study
Eslami (2015) Curi (2007) Cervin (2015) Antonello (2007) Pulli (2012) 0. Loss of Primary Patency (3 yrs) Wooster (2016) Ronchey (2015) Cervin (2015) Antonello (2007) Pulli (2013) Study
Curi (2007) Pulli (2012) Leake (2016) 0 Loss of Secondary Patency (3 yr) There is a clear difference in primary patency out to 3 years. OPAR has significantly lower risk of losing primary patency at 1 year (RR, 0.607), 2 years (RR, 0.661), and 3 years (RR, 0.580). This is most likely related to the early thrombotic complications cited before but remains true out to 3 years. Review of the 1-year primary patency forest plots shows consistently better outcomes at 1 year, with more variability at 3 years. Contrary to primary patency, there was no difference in secondary patency at any of the end points. At 3 years, there was a trend toward improved secondary patency with OPAR (RR, 0.642; P ¼ .07) that did not reach statistical significance. Open repair outcomes in patients with PAA have been well described. Huang Contrary to open repair, endovascular outcomes are more variable. Long-term secondary patency from single-center institutions has been reported at 76% to 100% at 5 years. [33] [34] [35] In this study, the weighted mean primary patency was 68% and the secondary patency was 80% at 3 years. There was significant variation in the five trials reporting midterm outcomes from 67% to 85%. This was also the case at 1 year, with four studies reporting <70% 1-year primary patency. 7, 12, 15, 27 Coinciding with this is the significantly higher early thrombotic complication rate of EPAR as discussed 14 There are limitations associated with this study. First, the quality of the studies limits the overall conclusions, as most are low quality. There is inherent bias for each patient based on clinical presentation, availability of conduit, available technology, and preferences of the surgeon that could not be accounted for in this study. These variables make selection bias difficult to eliminate, and to date the only randomized trial was in asymptomatic patients. Reporting bias is an important limitation because variables reported varied widely (complications) among studies, and more accurate variables (ie, major adverse limb events or limb preservation rates) were not reported.
This study represents the largest analysis of the management of PAAs to date. The overall literature is lacking in quality, and the need for well-controlled studies is critically important. At the time of this study, the Open Versus Endovascular Repair of Popliteal Artery Aneurysm (OVERPAR) study is still enrolling and should further clarify this topic. 36 Short-term outcomes still appear to favor EPAR, with shorter hospital stay and fewer wound infections. Overall complications showed no difference in the available literature; however, this is likely due to early experiences with EPAR. Evolutions in selection of patients and endovascular technology will likely demonstrate superiority in short-term outcomes. Perhaps the most clinically important end point to the durability is secondary patency, which showed no difference between the two procedures, at least for 3 years. Longterm comparative studies are currently not available. The results of this study are consistent with our experience supporting our current treatment strategy, which incorporates both techniques, the one complementary to the other. All patients are evaluated for potential EPAR with computed tomography angiography to evaluate sizing and pertinent PAA anatomy (potential landing zones, runoff, angulation). Equivocal patients undergo diagnostic angiography. If patients have favorable anatomy (two-vessel runoff or more with adequate landing zones of $15 mm of normal, nonaneurysmal artery), no available venous conduit, and high surgical morbidity risks (poor cardiopulmonary reserve), they undergo endovascular repair. Exceptions include patients with acute ischemia who need emergent revascularization or lytic therapy. Patients without favorable anatomy and who are at low risk for surgical morbidity undergo OPAR. This algorithm allows only patients with good anticipated outcomes to undergo EPAR, whereas all others are shifted toward OPAR (Fig 5) .
CONCLUSIONS
Endovascular repair for PAA has a lower wound complication rate and shorter length of hospital stay compared with open repair. This comes at the cost of an inferior primary patency but not secondary patency out to 3 years. Studies reporting long-term outcomes are lacking and necessary.
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